REAL-WORLD DATA ON INTRAVENOUS AND ORAL ANTINEOPLASTIC TREATMENTS OVER 20 YEARS (2005-2024) AT A TERTIARY HOSPITAL
Author(s)
JUAN FRANCISCO MARIN POZO1, ABENZA GUARDIOLA ASTRID, Pharm D2, MARIN CABA ALBERTO, Physics Degree2, MORENO BANEGAS JOSE, Pharm D2, TORRECILLA ABRIL MANUEL ANGEL, Pharm D2, DOMINGO ADRADOS ADRIAN, Pharm D2.
1JAEN, Spain, 2HOSPITAL UNIVERSITARIO DE JAEN, JAEN, Spain.
1JAEN, Spain, 2HOSPITAL UNIVERSITARIO DE JAEN, JAEN, Spain.
OBJECTIVES: To describe and compare the duration patterns of intravenous (IV) and oral antineoplastic treatments dispensed by a hospital onco-hematology pharmacy service over a 20-year period, analyzing temporal trends across successive four-year intervals.
METHODS: A retrospective observational study based on real-world dispensing records (2005-2024). Two datasets were analyzed: IV treatments (n=16,503 patients; 2005-2024) and oral treatments (n=5,875 patients; 2012-2024), resulting in a combined dataset of 22,378 records.
Duration was expressed in months. Descriptive statistics—median, mean, interquartile range (IQR), and 90th percentile (P90)—were calculated for each year and four-year period, including records with zero duration (single dispensing).
RESULTS: The volume of patients receiving IV treatment increased from 2,836 records (2005-2008) to 3,968 (2021-2024). The median duration of IV treatments remained stable across all periods (5.1-5.4 months; overall IQR: 2.2-14.7 months), whereas the mean duration dropped drastically from 19.3 months (2005) to 5.8 months (2024), driven by the disappearance of very long-duration treatments (P90: 38.1 months; maximum: 237.1 months).
The median duration of oral treatment was longer than that of intravenous treatment (6.1 months overall; IQR: 2.0-19.0 months), reaching 7.0 months (IQR: 2.7-21.5 months) in the 2020-2024 period. Mean oral treatment duration also decreased over time, falling from 21.1 months (in 2012) to 9.9 months (in 2024), with a 90th percentile (P90) of 44.5 months and a maximum of 172.9 months. Oral treatments accounted for 30% to 34% of combined activity during the overlap period (2013-2024).
CONCLUSIONS: The median treatment duration remained stable over a 20-year period, despite Incorporation of checkpoint inhibitor immunotherapy. Mean duration decreased markedly for both routes of administration, due to the end of data collection.
These findings provide a real-world benchmark for pharmacoeconomic modeling and resource planning in oncology pharmac
METHODS: A retrospective observational study based on real-world dispensing records (2005-2024). Two datasets were analyzed: IV treatments (n=16,503 patients; 2005-2024) and oral treatments (n=5,875 patients; 2012-2024), resulting in a combined dataset of 22,378 records.
Duration was expressed in months. Descriptive statistics—median, mean, interquartile range (IQR), and 90th percentile (P90)—were calculated for each year and four-year period, including records with zero duration (single dispensing).
RESULTS: The volume of patients receiving IV treatment increased from 2,836 records (2005-2008) to 3,968 (2021-2024). The median duration of IV treatments remained stable across all periods (5.1-5.4 months; overall IQR: 2.2-14.7 months), whereas the mean duration dropped drastically from 19.3 months (2005) to 5.8 months (2024), driven by the disappearance of very long-duration treatments (P90: 38.1 months; maximum: 237.1 months).
The median duration of oral treatment was longer than that of intravenous treatment (6.1 months overall; IQR: 2.0-19.0 months), reaching 7.0 months (IQR: 2.7-21.5 months) in the 2020-2024 period. Mean oral treatment duration also decreased over time, falling from 21.1 months (in 2012) to 9.9 months (in 2024), with a 90th percentile (P90) of 44.5 months and a maximum of 172.9 months. Oral treatments accounted for 30% to 34% of combined activity during the overlap period (2013-2024).
CONCLUSIONS: The median treatment duration remained stable over a 20-year period, despite Incorporation of checkpoint inhibitor immunotherapy. Mean duration decreased markedly for both routes of administration, due to the end of data collection.
These findings provide a real-world benchmark for pharmacoeconomic modeling and resource planning in oncology pharmac
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD171
Topic
Clinical Outcomes, Epidemiology & Public Health, Real World Data & Information Systems
Topic Subcategory
Distributed Data & Research Networks
Disease
Oncology, Personalized & Precision Medicine